Could Icahn Target Biogen Idec (BIIB) Next?
Tweet
Share
E-mail
Following news that Carl Icahn activist target BEA Systems Inc. (Nasdaq: BEAS) received a $17 per share takeover bid from Oracle (Nasdaq: ORCL), investors are looking at Biogen Idec (Nasdaq: BIIB) as Icahn's next possible activist target.
In the latest 13F from Carl Icahn's Icahn Management hedge fund the firm showed a 2,740,000 share stake in the biotech company. This is equal to about 1%.
In August, Icahn received FTC clearance to increase his stake in Biogen, but has yet to disclose an increased stake.
Icahn bought Biogen's stock because he believes the company is undervalued and is a takeover candidate.
Icahn has had success with biotech companies in the past - he was accumulating shares on MedImmune shortly before the company announced a sale to AstraZeneca PLC (NYSE: AZN).
Shares of Biogen Idec are up 1% today to $67.82.
In the latest 13F from Carl Icahn's Icahn Management hedge fund the firm showed a 2,740,000 share stake in the biotech company. This is equal to about 1%.
In August, Icahn received FTC clearance to increase his stake in Biogen, but has yet to disclose an increased stake.
Icahn bought Biogen's stock because he believes the company is undervalued and is a takeover candidate.
Icahn has had success with biotech companies in the past - he was accumulating shares on MedImmune shortly before the company announced a sale to AstraZeneca PLC (NYSE: AZN).
Shares of Biogen Idec are up 1% today to $67.82.
You May Also Be Interested In
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
- Hunterbrook bullish on Modine Manufacturing (MOD)
Create E-mail Alert Related Categories
Insiders' Blog, Rumors, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
